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Available online 9 March 2017Controlled biomaterial-based corticosteroid releasemight circumventmultiple injections and the accompanying
risks, such as hormone imbalance andmuscle weakness, in osteoarthritic (OA) patients. For this purpose, micro-
spheres were prepared from an amino acid-based polyester amide (PEA) platform and loaded with triamcino-
lone acetonide (TAA). TAA loaded microspheres were shown to release TAA for over 60 days in PBS.
Furthermore, the bioactivity lasted at least 28 days, demonstrated by a 80–95% inhibition of PGE2 production
using TNFα-stimulated chondrocyte culture, indicating inhibition of inflammation. Microspheres loaded with
the near infrared marker NIR780-iodide injected in healthy rat joints or joints with mild collagenase-induced
OA showed retention of the microspheres up till 70 days after injection. After intra-articular injection of TAA-
loaded microspheres, TAA was detectable in the serum until day seven. Synovial inflammation was significantly
lower in OA joints injected with TAA-loaded microspheres based on histological Krenn scores. Injection of TAA-
loaded nor empty microspheres had no effect on cartilage integrity as determined by Mankin scoring. In conclu-
sion, the PEA platform shows safety and efficacy upon intra-articular injection, and its extended degradation and
release profiles compared to the currently used PLGA platforms may render it a good alternative. Even though
further in vivo studiesmay need to address dosing and readout parameters such as pain, no effect on cartilage pa-
thology was found and inflammation was effectively lowered in OA joints.ers).
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Osteoarthritis (OA) is a chronic degenerative joint disease, burden-
ing patients worldwide, with the knee being one of the commonly af-
fected joints [1,2]. The burden for OA is expected to increase, given the
rapid increase in prevalence of its risk factors, such as age and obesity
[2,3]. The aetiology of OA is still not fully understood, but both cartilage
and synovial tissue pathogenesis contribute to this joint disease [4]. Sy-
novial inflammation and the inflammation mediators produced have
found to be elevated in OA patients and influences OA processes andtheim, Paulinenweg 1,
an open access article undersymptoms [4–6]. Corticosteroids administered via intra-articular (IA)
injections are being used to relieve pain in OA patients [7]. Their effects
are of limited duration since they are cleared out of the synovial space
and human body relatively fast [8–10]. Repeated applications are there-
fore needed to sustain the pain relief over a longer period of time, al-
though these are associated with adverse side effects, such as
infection, muscle weakness and hormone imbalance [7,11–13].
Applying CS in controlled release platforms can prevent fast clear-
ance and overcome the disadvantages of repeated injections. Ideally,
biomaterials used for these purposes show little or no local inflammato-
ry responses and have a slow degradation profile. Biodegradable poly-
mers have already been widely used in orthopaedic applications, but
foreign body reaction to the biomaterial leading to further tissue degen-
eration are a safety concern [14–16]. Moreover, most of the platforms
described give sustained release over a relative short period of days,
compared to the clinical need of months to years. One of the FDA-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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is poly(lactic-co glycolic acid) (PLGA). PGLA is a commonly used bioma-
terial to achieve controlled release of drugs in OA [17–20]. Typically in
vivo, release was demonstrated for 4–32 days [17,20–22]. Recently, in
a clinical trial with osteoarthritis patients, a PLGA-based controlled re-
lease formulation of TAA resulted in a more profound pain reduction
than a single intra-articular bolus injection [23]. However, the analgesic
effect from the sustained TAA release was only superior to bolus injec-
tions between five and tenweeks after injection. A further disadvantage
of PGLA is its degradation into lactic and glycolic acid, with a risk of in-
ducing toxic local pH levels [18,24].
Recently, a polyester amide (PEA) biomaterial platform was de-
scribed that induced a minor foreign body reaction in the eye, knee
joint and the intervertebral disc [25–27]. Furthermore, it has been
shown to be biocompatible upon injection in those tissues with slow
clearance rates due to the avascular environment, with the eye and in-
tervertebral disc known to be immunoprivileged [28]. This platform is
built of amino acid moieties and hence degradation will not result in
toxic conditions [29–31]. PEA particle erosion is dependent on serine
protease activity and hence no erosion occurs in vitro in PBS [32].
More importantly, PEA microspheres are a suitable platform for
prolonged release of small molecule drugs such as corticosteroids, as
shown by their in vitro release of celecoxib of 80 days [27]. In addition,
PEA microspheres were injected into a rat degenerative articular joint,
a location that is readily accessible to cells from the acquired and the in-
nate immune system and hence more likely to show inflammatory re-
sponses to biomaterials. Whether the clinically used corticoid TAA,
applied in sustained release, is safe and effective in reducing inflamma-
tory processes still has to be determined. Hence, in the current study,
PEAmicrospheres loadedwith TAAwere characterized in terms of load-
ing and release in vitro, using a cell-based model of induced inflamma-
tion [19]. Furthermore, the release of TAA into the systemic circulation
and its effects on articular cartilage and synovial lining inflammation
in a rat model of osteoarthritis was compared to a bolus of TAA.
2. Materials and methods
2.1. Preparation and loading of polyester amide microspheres
PEA was synthesized in accordance to procedures reported previ-
ously [25,26,29]. For the preparation of microspheres, PEA was dis-
solved in dichloromethane (Merck Millipore). 20 wt% triamcinolone
acetonide was added to the solution and homogenized by ultrasound.
The suspension was added to 20 ml of an aqueous solution containing
surfactants for stabilization (1 wt% of poly(vinyl alcohol and 2.5 wt%
NaCl, SigmaAldrich) under high shear, using an ultra-Turrax. After a sta-
ble suspension was obtained the particles were allowed to harden in
100 ml of water containing 1 wt% of poly(vinyl alcohol) and 2.5 wt%
NaCl for 12 h. Excess of water and surfactant was removed by rinsing
and centrifugation. Finally, particles were frozen and dried. Preparation
procedures of microspheres loaded with IR-780 iodide are exactly the
same, but are loaded with 0.2% w/w of IR 780 iodide instead of TAA
and dissolved in DCM. Size distribution of PEA particles was measured
by static light scattering and ranged from 8 to 50 μm.
2.2. TAA release by PEA microspheres in vitro
2.2.1. In vitro release of TAA in PBS buffer
Release kinetics of TAA from PEA microspheres in PBS buffer were
determined by incubation in a volume of 50 ml at 37 °C, of which
45 ml buffer was renewed. Buffer exchange was performed twice the
first day, every day up to day 3 and from there every 3–4 days up to
day 24. After that, the buffer was renewed on aweekly basis. Size distri-
bution of TAA-loaded particleswas determinedwith Static Light scatter-
ing, using a Malvern Mastersizer 2000. Approximately 10 mg of
microparticles were accurately weighted and dissolved in appropriateamount of methanol and shaken until a clear solution was obtained.
The sampleswere analysed for TAA concentration by High performance
Liquid chromatography (HPLC), using a Waters e2695 Alliance HPLC
with UV detector. The method was obtained from the pharmacopoeia
collection.
2.2.2. Chondrocyte isolation and culture
Articular cartilage was harvested from knee joints derived from pa-
tients undergoing arthroplasty. Anonymous use of redundant tissue
from joint surgery used for scientific purposes is part of the standard
treatment agreement with patients from the University Medical Center
Utrecht [33]. Chondrocytes were isolated by a 3-hour enzymatic diges-
tion in 0.1% pronase (Roche, Mannheim, Germany), followed by an
overnight enzymatic digestion in 0.04% collagenase type 2
(Worthington Biochemical, Lakewood, NJ, USA) at 37 °C. Undigested de-
bris was removed using a 70 μm-cell strainer (Becton Dickson, Franklin
Lakes, USA). The resulting suspension of cells was washed in PBS and
centrifuged. Afterwards, the cells were re-suspended in expansion me-
dium (3000 cells/cm2) consisting of DMEM (Gibco® Life Technologies,
Carlsbad, CA, USA) containing 4.5 mg/ml glucose, 0.8 mg/ml glycyl-L-
glutamine, 10% foetal bovine serum (FBS) (HyClone® Thermo Fisher
Scientific, Waltham, MA, USA), 100 U/ml penicillin, 100 μg/ml strepto-
mycin (Gibco® Life Technologies) and 10 ng/ml basic fibroblast growth
factor (bFGF) (R&D Systems,Minneapolis,MN, USA). The cellswere cul-
tured at 37 °C and 5% CO2. The culture medium was renewed every 3–
4 days. At passage two, cells were frozen in aliquots of 1 million per
vial in freezing medium, containing 10% DMSO (Merck) and 20% FBS
in DMEM. For each release experiment, cells of the same donor were
used at each of the successive time intervals.
2.2.3. Release and bioactivity of TAA from microspheres
Oneday before the experiment, cellswere thawed and seeded onto a
24-well culture plate, at a density of 40,000 cells perwell. Cellswere cul-
tured inmedium containingDMEM (including glucose and glycyl-L-glu-
tamine), 10% FBS and antibiotics. The following day, the medium was
renewed before starting the experiment. PEA microspheres, loaded
with TAA at 20%, were dispersed in a total of 1 ml culture medium
and placed in Transwell® baskets at 8.7 or 0.87 μg per well (0.4 μm
pore size, polycarbonate membrane) (Corning, Amsterdam, The Neth-
erlands) over the plated cells. Unloaded microspheres were taken as
controls. Cells and microspheres were pre-incubated for 4 h at 37 °C,
at 5% CO2 and 95% humidity. Subsequently, tumour necrosis factor
alpha (TNFα) (eBioscience, San Diego, CA, USA) was added at a final
concentration of 10 ng/ml to the culture medium in all conditions.
Cells and microspheres were co-incubated further for another 72 h be-
fore the microspheres were transferred to a new 24-well culture plate
containing cells seeded according to the procedure described above.
This procedurewas repeated 9 times accounting to a total release period
of 27 days. Cells treated with 10−7 M or 10−8 M TAA directly added to
the culture medium and continuously renewed, were included as posi-
tive control in each time interval. Each condition was analysed in 4 rep-
licates (n = 4) and experiments were performed for three different
donors. At every 72-hour time point medium was collected and cells
were lysed in KDalert™ Lysis Buffer (Ambion®, Life Technologies). Sam-
ples were stored at −80 °C until further analysis if not used
immediately.
2.2.4. PGE2 release
Cell culture medium was collected at day 3, 6, 9, 12, 15, 18, 21, 24
and 27 and stored at−80 °C;mediawere brought to room temperature
immediately prior to PGE2measurement. PGE2 wasmeasured using the
enzyme immunoassay Prostaglandin E2 Parameter Assay Kit (R&D Sys-
tems) following the manufacturer's instructions. Colorimetric intensity
was determined using the Benchmark Microplate Reader (Bio-Rad) at
450 nm. The readings were subtracted by those at 540 nm. The concen-
tration of PGE2 in the samples was determined by using a calibration
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intensity of the response of OA chondrocytes to TNF varied between do-
nors, for each condition normalized to the average PGE2 content of con-
trols, which received TNFα only. The average values of controls were set
to be 100%.
2.3. Study design
Animal experiments were carried out under the approved protocol
(DEC# 2013.III.04.036) of the Utrecht University Ethical Committee for
Animal Care andUse, following the central commission of animal exper-
iments guidelines for animal research in the Netherlands. 16 female
adult Sprague-Dawley rats (Harlan Laboratories, Horst, The Nether-
lands) were used in this study: 4 to test the degradation rate of micro-
spheres and 12 to determine safety and release of microspheres
loadedwith triamcinolone acetonide. Animalswere allowed to acclima-
tize for oneweek andwere housed in groups. Ad libitum food andwater
was provided. Intra-articular injections and Near-Infrared fluorescence
(NIRF) imagingwere performed under isoflurane anaesthesia (4–5% in-
duction, 1–2% for maintenance).
2.3.1. Induction of osteoarthritis in rat knee joints
OA was induced via intra-articular injection of 30U type II collage-
nase through the patellar ligament using a 30G insulin needle (Sigma-
Aldrich) in 25 μl, dissolved in NaCl + 1 mM CaCl dihydrate (Sigma-Al-
drich). For the retention of microspheres by NIRF imaging, in 4 rats OA
was induced unilaterally and for the evaluation of safety and TAA re-
lease profiles, OA was induced bilaterally by collagenase injection in
12 rats. Postoperatively, animals received 0.05 mg/kg Buprenofin
(Temgesic) subcutaneously as prophylactic analgesia.
One week after bilateral OA induction, 6 rats were intra-articularly
injected with 25 μl of PEA microspheres loaded with triamcinolone
(50 mg/ml particles containing 18 wt% TAA, total dosage of 250 μg), 6
rats with 25 μl TAA bolus injection (10 mg/ml, Kenacort; Bristol-Myers
Squibb, Woerden, The Netherlands) in the experimental joint. Contra-
lateral knees of rats were injected intra-articularly with saline or
50 mg/ml empty microspheres as control. After injection, blood for
serum analysis was drawn via tail vein. This was repeated at one hour
interval on the first day, twice daily on the following 2–5 days, daily
on day 6–14 and once at day 16, 18, 20, 22, 25, 28, 35, 42 and 49.
Blood samples were cooled and centrifuged, and serum was frozen at
−20 °C. After these seven weeks, animals were sacrificed and knees
were prepared for histology.
2.4. PEA microsphere retention in vivo
2.4.1. NIRF780-iodide injection and imaging
Oneweek after OA induction, 25 μl microspheres (50mg/ml) loaded
with 0.2% w/w of IR 780 iodide were injected intra-articularly in both
knees of 4 rats. Every other week, in both joints the intensity of
NIRF780-iodide was determined in sedated rats. Rats were scanned
using an Ivis spectrum device (Perkin Elmer). Spectral unmixing excita-
tion 675 nm and emission 740, 760, 780, 800 and 820 nm was used.
Data were analysed using Living Image 4.3 software (Perkin Elmer).
After ten weeks, rats were euthanized using CO2/O2 asphyxiation, sub-
sequently both legs were collected and removed of skin and scanned
again.
2.5. Biological efficacy of TAA-loaded PEA microspheres in vivo
2.5.1. LC-MS/MS analysis of serum
Concentrations of triamcinolone acetonide in rat serumwere deter-
mined bymeans of a LC-MS/MSmethodusing a Thermo Fisher Scientific
(Waltham, MA) triple quadrupole Quantum Acces LC-MS/MS system.
Sample preparation involved a liquid– liquid extraction stepwithmeth-
yl tert-butyl ether (TBME) using triamcinolone acetonide-13C3 asinternal standard. After centrifugation, the organic supernatant was re-
moved and evaporated to dryness. The residue was reconstituted with
50 μl 0.1% formic acid and injected for LC–MS/MS analysis. The method
showed linearity over the range of 0.5–15.0 μg/l with a regression coef-
ficient of 0.996. The analytical accuracy and precision are within the
maximum tolerated bias and CV, 10% for LLOQ (0.5 μg/l), 7% for
the LOW (2.0 μg/l), 6% for the MED (7.5 μg/l) and 4% for the HIGH
(12.0 μg/l).
2.5.2. Tissue processing and histology of synovium and cartilage
All jointswere decalcified in 10% formic acid solution in combination
with microwaving [34], thereafter embedded in paraffin. 5 μm knee
joint sections were made and stained either with Safranin-O/Fast
green or haematoxylin and eosin to evaluate cartilage damage and sy-
novial tissue inflammation, respectively, using Mankin and Krenn scor-
ing systems. Krenn score indicates no synovitis with grade 0–1 and high
grade synovitis with grade 5–9 [35]. Mankin score is ranging from
healthy grade 0 to total joint destruction grade 14 [36]. Scoring was
done by two blinded observers (SC and SP).
2.6. Statistical analyses
All data were analysed using IBM® SPSS® Statistics version 21. Data
concerning PGE2 production and serum TAA levels were logarithmically
transformed first. Then, assumptions of normality of residuals and ho-
mogeneity of variance were met. Linear mixed models was used to an-
alyse repeated measurements, followed by pairwise comparisons with
LSD adjustment. Model selection was based on the lowest Akaike Infor-
mation Criterion. Donor served as random effect factor and treatment,
time and their interaction served asfixed effect factors in thismodel. Re-
gression coefficients were estimated by themaximum likelihoodmeth-
od. Krenn andMankin data (indicating synovitis and cartilage integrity,
respectively) met assumptions of normal distributed residuals and ho-
moscedasticity and were therefore not transformed. ANOVA with
Tukey-HSD post-hoc correction was used to observe differences be-
tween group means. p b 0.05 is found significant.
3. Results
3.1. Characterization of TAA loaded microspheres
SEM analysis of the loaded microspheres showed part of the TAA
was incorporated as crystals (Fig. 1A). TAA release in PBS buffer at 37
°C showed an initial burst at day one with a gradual increase of TAA re-
lease up to 50% cumulative release after 60 days (Fig. 1B). The average
size of the microparticles was 22.4 μm, with a dispersity index of
1.205. Loading was 20 wt%, with 12% located outside of the spheres.
Due to the buffer exchange ~8% of particles were lost and 35% of TAA
was recovered.
3.2. Bioactivity by released TAA
PGE2 production levels were negligible in cells not treated with
TNFα or only exposed to medium containing empty microspheres
(data not shown). When TNFα was added to the cells, sufficient PGE2
was produced. However, a transient increase in PGE2 production at
day 4was found in cells treatedwith TNFα in the presence of emptymi-
crospheres compared to cells treated with TNFα in the absence of
empty microspheres (p b 0.05, Fig. 2a).
When TAA loaded in microspheres (0.435 mg, equivalent to 0.1 μM
(“MS-TAA 10−7 M”) if released immediately) was added to the culture
system, PGE2 production was reduced to b5% of non-treated TNFα-
stimulated cells until day 12, after which PGE2 production levels in-
creased to 20% by the end of the culture period. The lower dosage of
TAA released from the microspheres (equivalent to 0.01 μM (“MS-TAA
10−8 M”) at 1 ml) reduced PGE2 production to 8% non-treated TNFα-
Fig. 1.A) SEMof TAA loadedmicrospheres. B) TAA release from loadedmicrospheres in PBS buffer, after 60 days, showed an initial burst release at thefirst day and a gradual increase up to
50%.
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ing the lower dosage thus resulted in a faster loss of PGE2 inhibition.
However, both dosages TAA released from the microspheres still
showed an over 80% inhibition over the remainder of the culture period
(Fig. 2b). Free TAA in two different concentrations (0.435 mg, equiva-
lent to 0.1 μM (“TAA 10−7 M”) and 0.0435 mg, equivalent to 0.01 μM
(“TAA 10−8 M”) directly added to the culture medium at each time in-
terval also completely inhibited PGE2 production to below 5% (p b 0.05,
Fig. 2).
3.3. Microsphere retention in rat joints
In 7 of the 8 knees, clear signal was visible after intra-articular injec-
tion of IR780-loaded microspheres. Injection appeared to have failed in
one out of eight rat knees, as no signal was observed at any of the time
points. In the 7 knees with signal, a gradual decline of signal over
70 days was observed (Fig. 3), which was still detectable in vivo in
two out of seven joints. Removal of the skin after euthanasia revealed
6 out of the 7 remaining joints to contain NIRF label (Fig. 3). The loss
of signal over time seemed not reliant of the presence of osteoarthritic
processes in the joint, despite a trend towards a decreased signal com-
pared to the contralateral healthy knee. The signal obtained aroundthe front paws of the rat, and in some cases over the lower abdomen,
was autofluorescence, as verified by spectral unmixing emission analy-
sis of the upper region (front paws) separately from the bottom region
(hind paws), where we noted a shift in emission from 800 nm to
760 nm.
3.4. Release kinetics TAA
Serum TAA levels weremeasured to indirectly determine release ki-
netics and systemic load. Systemic TAAwas detected both in animals re-
ceiving intra-articular TAA by bolus or microspheres. Peak serum levels
of TAAwere higher with bolus injections (45 μg/ml) than in the slow re-
lease system (12.5 μg/ml, p b 0.05), while bolus TAA was detectable in
systemic circulation until 120-hour post injection and TAA released
from microspheres 170-hour post injection, Fig. 4).
3.5. Joint histology
H&E stained sections were evaluated for possible remainders of mi-
crospheres but these were not encountered. Seven weeks after induction
of OA, synovial inflammation (3 out of 9 onKrenn score) and cartilage de-
generation (5 out of 14 onMankin score)weremild (Fig. 5). Therewas no
Fig. 2. PGE2 production was inhibited during the total culture period upon TAA treatment,
regardless of dose and formation, compared to chondrocytes treated solely with TNFα
(100%, orange dotted line) except in the presence of empty microspheres (grey solid
line). Negative control indicates chondrocytes without TNFα (black dotted line), TNFα
+ TAA 10−7 M (dark blue dotted line) and TNFα + TAA 10−8 M (light blue dotted line)
represent free 0.1 or 0.01 μM TAA, respectively, added to the culture medium.
Corresponding TAA dosages in microspheres are indicated with TNFα + MS-TAA
10−7 M (dark blue solid line) and TNFα + MS-TAA 10−8 M (light blue solid line).
Results are shown as average mean ± SD for three donors with six replicates per donor.
*p b 0.05.
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tive changes in the joints injected with empty microspheres. However,
TAA administered in microspheres significantly decreased synovial lining
thickness and inflammatory infiltrate compared to microsphere saline-
injected joints (p b 0.05). No clear effects were noted of either controlled
release of TAA nor bolus TAA on cartilage integrity.
4. Discussion
Biomaterials encapsulating corticosteroids for OA treatment devel-
oped to sustain their release locally are a promising approach towards
long term relief of OA-associated pain [37–39]. Here, a previously de-
scribed polyester amide-based biomaterial platform was characterized
for its safety, retention and applicability for local delivery in the joint
over a relatively long period of time. The release of TAA from this plat-
form lasted for over 60 days in PBS. Furthermore, in a chondrocyte-
based in vitro system, inflammation was reduced to 5–20% over the
full period of 28 days by microspheres loaded at a single dose of TAA
equivalent to TAA added directly. Upon intra-articular (IA) injection in
vivo, retention of PEA microspheres loaded with near infrared labelwas found for over two months after injection. At the histological
level, the microspheres could not be traced back after seven weeks,
nor did their presence in the joints induce enhanced inflammation or
cartilage degeneration. TAA inmicrospheres nor as bolus resulted in im-
proved cartilage integrity. However, synovial inflammation was effec-
tively reduced in OA joints receiving sustained TAA release from
microspheres but not by bolus TAA. Furthermore, controlled release of
TAA frommicrospheres was confirmed by decreased peak serum levels
compared to the bolus of the same amount of TAA, with a slightly
prolonged presence in the systemic circulation.
Focussing on the anti-inflammatory action in the current study, TAA
released from PEA-based microspheres remained bioactive over
4 weeks in an in vitro assay based on inflammatory OA chondrocytes.
This assay is used to determine the potential of TAA to supress inflam-
mation and was previously optimized for optimal inflammatory re-
sponse of the cells, and hence did not aim to mimic “natural”
chondrocyte behaviour [19]. In the same in vitro bioactivity assay inves-
tigating TAA release from PGLAmicrospheres, PGE2 production was re-
pressed up to 38% after 27 days, using a ten-fold lower dosage of TAA.
When comparing the same amount of TAA released from both micro-
spheres (435 ng, equivalent to 10−8 M TAA if released immediately),
PGLA microspheres were only able to reduce PGE2 production to 29%
after 27 days as opposed to the 80% reduction found in this study after
21 days of culturing [19]. This is in line with available data on PLGA-
based platforms, which typically show a release in culture medium or
in vivo varying from days to weeks. For example, controlled
temporospatial delivery of bovine serum albumin proteins by PLGAmi-
crospheres showed degradation in a relatively short period of 14 days
subcutaneously in mice [22]. The prolonged stability and release of the
current PEA-based platforms thus appears to confer an advantage over
other faster releasing platforms. PEA compatibility was already shown
in preclinical settings targeting the eye or intervertebral disc degenera-
tion [25,26]. The current study shows the applicability of this platform
in the highly immune responsive environment of the articular joint,
which is in accordance with a recently published study evaluating the
small molecule celecoxib in OA joints [27].
The importance of reducing the systemic load after intra-articular
application of corticosteroids is shown in previous pharmacokinetics
studies of IA injection of TAA, where TAA was detectable in plasma af-
terwards and incurred impaired wound healing, infection, muscle
weakness and hormone imbalance [11,12,40]. In humans, hydrocorti-
sone levels could be suppressed after IA injection of TAA suspension
(40 mg) and remained repressed for three days, suggesting a systemic
reaction with serum TAA levels even though these fell below the
1 ng/ml detection limit [40]. Therefore, minimizing systemic TAA load
is an important feature of this platform since it indirectly decreases
risks for adverse side effects caused by systemic TAA. After 120 h post
IA injection, serum TAA levels were diminished to undetectable levels
(b0.5 ng/ml). Surprisingly, compared to a previously described PLGA-
based platform, systemic TAA levels in Lewis rats 120 h post IA injection
of 0.28mgTAAwere still approximately 0.75 ng/ml, systemic TAA levels
in the current study (250 μg TAA-MS) diminished faster [20]. Although
loss of solutes such as cytokines in the human jointwere shown to occur
within 3 days [10], the prolonged systemic levels of TAA after intra-ar-
ticular injection, sometimes up to 2 weeks after injections, can be ex-
plained by the low solubility of TAA in water, naturally forming
crystals allowing for delayed delivery [40]. However, the TAA crystals
in TAA suspension injections have shown to be cytotoxic in direct con-
tact with cell membranes [41,42], which is another advantage of using
slow release formulations.
Application of controlled release of TAA in the rat model of OA did
not show a clear improvement of cartilage histology, however, neither
did the TAAbolus. Even so, synovial inflammationwas clearly decreased
using TAA-loadedmicrospheres. Possibly the limited room for improve-
ment in terms of cartilage degeneration has precluded a more pro-
nounced effect on cartilage integrity of the administration of either
Fig. 3. PEAmicrosphere retention in vivo. In four rats, OA was induced in the left knee and contralateral knee served as healthy control. All joints were intra-articularly injected with PEA
microspheres, loadedwith IR 780 iodide. Here, rats are shown that were subjected to fluorescence optical imaging pre-injection, at day 1, 28, 70 and at day 70 ex vivo. The signal obtained
around the front paws and lower abdomen was autofluorescence.
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influence cartilagemetabolism processes by its effect on synovial tissue.
A previous study already have demonstrated an inhibition in GAG pro-
duction in single cartilage explants while this effect was counteracted
by TAA in cocultures of synovium and cartilage explants [43]. Also,Fig. 4. Serum TAA levels of rats were determined at several time-points. Release profiles of
bolus and TAA-loaded microspheres intra-articular injections in OA joint represented in
dashed and solid lines, respectively. Bullets show mean ± SEM for six rats per group.
Insert provides a more detailed overview of serum TAA levels of the first 24 h post-
injection. *p b 0.05.other more severe OAmodels may possibly enable intra-articularly ap-
plied TAA to show a pronounced effect. The effect of corticosteroids on
joint tissue integrity in vivo has been studied to a limited extent. De-
creased cartilage ECM synthesis or degradation after treatment in vitro
[44–46] as well as in vivo were found [47,48]. Notably, these studies
were based on corticosteroid formulations of which the vehicle excipi-
ents were shown to be toxic [49,50], so it cannot be excluded that
these negative effects were not caused by the corticosteroids. In con-
trast, many OA animal studies demonstrated a decrease of OA progres-
sion or a protective role of corticosteroid injections, based on
histological and biochemical findings [20,51–55].Whether this is repre-
sentative of the human situation is unknown. In the current study, dos-
ing may have been suboptimal. Although the used dosages were based
on human vs rat synovial fluid joint volumes as conversion factor,
which is superior to dosing based on body weight scaling [52], species
specific characteristics in TAA signalling may require higher dosages
for effects on cartilage degeneration. Clinical studiesmight in fact repre-
sent the best tool, with no severe harmful effects on arthritic joints
found at the radiographic level following repeated intra-articular TAA
injections [23,56–58]. A systematic review described beneficial effects
of IA corticosteroid suspension injections, Kenalog® mostly used, last-
ing up to 4weeks although it was argued unlikely that clinical effects re-
main after this period [59]. Whether systemic side-effects of controlled
release of TAA by IA injections arise has not been investigated exten-
sively yet. Only one recent phase-II randomized double-blind clinical
study assessed the efficacy of IA injection of TAA PGLA-microparticles
and described no adverse effects clinically and at the radiographic
level during the seven weeks study period [23]. Typically the clinical
outcome parameter of clinical studies on OA is pain, and in the latter
study this was suppressed more strongly with the microspheres than
Fig. 5.Cartilage degeneration (A) and synovitis (B) scores of rats treatedwithmicrosphere
or bolus TAA injections. In twelve rats, OA was induced in both joints. Cartilage and
synovial tissue histology was determined using Mankin and Krenn scores, respectively,
of six rats intra-articularly injected with TAA bolus or microsphere formation (dotted
bars). Contralateral joints were injected with saline and served as control (solid bars).
Mankin score is ranging from healthy grade 0 to total joint destruction grade 14. Krenn
score indicates no synovitis with grade 0–1 and high grade synovitis with grade 5–9.
Bars represent mean ± SD for six rats per group. *p b 0.05. Synovial tissue stained for
Haematoxylin & Eosin (C) of all four treatments. Scale bar = 20 μm.
70 I. Rudnik-Jansen et al. / Journal of Controlled Release 253 (2017) 64–72using the same quantity of TAA in suspension at the same dose. Possibly
pain would in in vivo OA models in general also be a more relevant pa-
rameter, provided no adverse effects at the histological and systemic
level are noted.
Other delivery platforms, in addition to PGLA and the current bioma-
terial, were recently developed for sustained drug release in preclinical
studies [17,60,61]. Nanoparticles, scaffolds or hydrogels of diverse bio-
materials such as chitosan, hyaluronic acid or PLGA have been tested
in rodent OA joints and while in general these did not evoke an addi-
tional inflammatory effect, their therapeutic effect on tissue regenera-
tion or pain was often inconclusive and needs further investigation
[62,63]. PEA-based platforms are rather newly used as controlled re-
lease systems and their retention and possible therapeutic effects in
vivo have not been extensively described before. Here, polymer reten-
tion was shown to be prolonged compared to other platforms with sig-
nal from the near infrared marker present up until 70 days after
injection indicating not all microspheres were degraded at this timepoint.Whilewe cannotwith certainty exclude that the loss of NIR signal
is due to the loss of microspheres from the joint, the presence of the en-
dothelial barrier in the synovium makes this highly unlikely. The
prolonged retention of NIR-loaded microspheres in the joint is well in
line with the b100% TAA released in PBS found in the same time period.
Although this cannot directly be extrapolated towards the in vivo re-
lease of a hydrophobic small molecule drug such as TAA, this suggests
much longer release periods are possible using this biomaterial
platform.
PEA based platforms are attractive for novel controlled release strat-
egies. They have already shown to provide effective controlled release in
vitro by releasing anti-inflammatory drugs and thereby attenuating for-
eign body inflammatory responses in vitro or only provoke slight foreign
body reactions reflecting in inflammatory cell infiltrate in vivo [25,26,31,
64]. In the knee, no foreign body reaction was observed histologically in
vivo, nor was an additional degenerative effect noted, in linewith a pre-
vious finding showing a lack of synovial thickening and necrosis after
injection [23]. However, we cannot exclude that these responses have
occurred at earlier time points. Microsphere size has been shown im-
portant for their entrapment in joint tissues after IA injection [21,23,
57]. The microspheres used in the present study could be expected to
be sequestered as subsynovial granulation plaques due to the present
macrophages [27]. However, PEA microspheres were not recognized
in the histological sections, possibly due to the embedding and histolog-
ical staining procedures [21]. Complete degradation of themicrospheres
is an unlikely explanation for the lack of an inflammatory response, as
NIR label incorporation showed retention of label-containing micro-
spheres at 10 weeks. Previously, hydrolysis of knee joints, twelve
weeks after IA injection showed still 20% of PEA polymer, while PEA
degradation was significantly higher in OA rat joints compared to con-
tralateral healthy joints injected with empty microspheres [27]. In the
current study, amilder OAmodel was used, but PEAmicrospheres load-
ed with TAA still decreased synovial inflammation successfully. This
suggests that these PEA microspheres loaded with the corticosteroid
often used in the clinics can potentially be an improved pain treatment
for OA patients by reducing inflammatory responses.5. Conclusion
A safe route of administration of incorporated triamcinolone
acetonide in PEA microspheres was confirmed by intra-articular injec-
tion in OA joints. Moreover, the slow degradation of the microspheres
makes it a suitable tool for relieving inflammation and pain locally for
a longer period of time. We have shown here that this new generation
of microspheres provide a safe platform, by 1) no considerable foreign
body reaction, 2) decreased peak serum TAA levels and 3) decreased sy-
novial inflammation, which renders it an applicable controlled release
platform for clinical use. Further studies should focus on the appropriate
dosing of corticosteroids locally in mild to severe OA joints and their ef-
fect on suppressing pain.Acknowledgments
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